植込み型ポートの市場調査レポート：タイプ別（シリコン、ポリウレタン、チタン）、用途別（化学療法、抗生物質療法、総合非経口栄養、輸血）、エンドユーザー別（病院、外来手術センター、専門クリニック）、挿入方法別（外科的挿入、経皮的挿入）、2035年までの予測
Implantable Port Market Research Report by Type (Silicone, Polyurethane, Titanium), By Application (Chemotherapy, Antibiotic Therapy, Total Parenteral Nutrition, Blood Transfusion), By End User (Hospitals, Ambulatory Surgical Centers, Specialized Clinics), By Insertion Method (Surgical Insertion, Percutaneous Insertion) Forecast to 2035
植込み型ポートの市場調査レポート：タイプ別（シリコン、ポリウレタン、チタン）、用途別（化学療法、抗生物質療法、総合非経口栄養、輸血）、エンドユーザー別（病院、外来手術センター、専門クリニック）、挿... もっと見る
サマリー 植込み型ポートの市場調査レポート：タイプ別（シリコン、ポリウレタン、チタン）、用途別（化学療法、抗生物質療法、総合非経口栄養、輸血）、エンドユーザー別（病院、外来手術センター、専門クリニック）、挿入方法別（外科的挿入、経皮的挿入）、2035年までの予測
市場概要
MRFRの分析によると、植込み型ポート市場規模は2024年までに32億9,028万米ドルに達すると予測される。植込み型ポート市場は、2025年から2035年にかけて年平均成長率6.21％で成長すると推定される。
植え込み型ポート市場業界を前進させている主な理由の1つは、世界中で慢性疾患が増加していることである。がん、糖尿病、腎臓病がますます一般的になるにつれて、植え込み型ポートのような信頼性が高く効果的な長期的医薬品送達技術に対する需要が高まっている。これらのポートは、定期的な輸液や採血を必要とする患者にとって効率的なソリューションであり、医療従事者が最小限の不快感や結果で薬剤を投与することを可能にする。患者の予後を改善することにますます重点を置くようになった医療制度と、長期にわたる薬剤投与の必要性から、埋め込み型ポート技術が潜在的な選択肢として浮上している。さらに、頻繁な通院を必要としない外来治療や慢性疾患治療への需要が高まっていることも、こうした機器の魅力と必要性を高めている。技術の進歩も植込み型ポートのデザインと機能性を向上させ、その結果、医療専門家や患者の間でより広く受け入れられるようになった。安全性、有効性、快適性の面で植込み型ポートを使用する利点に対する認識が高まったことも、その採用を加速させている。これらすべての理由が、植込み型ポート市場の堅調な成長に寄与している。
市場セグメントの洞察
世界の植え込み型ポート市場は、材料の種類によってシリコーン、ポリウレタン、チタンの3つのセグメントに分けられる。チタンは2024年に最大の市場シェアを占め、予測期間中（2025-2035年）に最も急成長が見込まれている。
市場は用途別に4つのセグメントに分けられる：化学療法、抗生物質療法、完全非経口栄養、輸血。
市場はエンドユーザーに基づいて3つのセグメントに分けられる：病院、外来手術センター、専門クリニック。
市場は挿入方法に基づいて2つのセグメントに分けられている：外科的および経皮的。
地域別洞察
世界の埋め込み型ポート市場は5つの地域に分けられる：北米、欧州、アジア太平洋、南米、中東・アフリカである。北米は2024年に最大の市場シェアを占め、2035年には24億1,661万ドルに達すると予測されている。しかし、アジア太平洋地域は予測期間中最も速いCAGR 8.32％で発展すると予想されている。
北米の埋め込み型ポート市場は、2024年には13億8,275万米ドルで、予測期間にはCAGR 5.20%で増加する見込みである。北米はさらに米国とカナダに分けられる。
欧州の埋め込み型ポート市場は2024年に9億7,235万ドルで、予測期間のCAGRは6.41%で増加が見込まれている。
アジア太平洋地域の植込み型ポート市場は、2024年に6億6,757万ドル規模であり、予測期間のCAGRは8.32%で増加する見込みである。アジア太平洋地域はさらに、中国、インド、日本、韓国、マレーシア、タイ、インドネシア、その他のアジア太平洋地域に分けられる。
主要プレイヤー
Easton Medical社、Baxter International社、Zyga Technology社、Terumo社、Apex Medical Technologies社、Medtronic社、Boston Scientific社、Cook Medical社、AngioDynamics社、Kirwan Surgical Products社、Smith's Medical社、Nitinol Devices Corporation社、C R Bard社、Stryker社、Halyard Health社などが植込み型ポート市場の主要プレーヤーである。
ページTOPに戻る
目次 目次
1.
1.
1.
1.
1.
1.
1.
2.
2.
2.
2.
3.
3.
3.
3.
3.
3.
3.
3.
3.
3.
3.
3.
3.
3.
3.
3.
3.
3.
4.
4.
4.
4.
4.
4.
4.
4.
4.
4.
4.
5.
5.
5.
5.
5.
5.
5.
5.
5.
5.
5.
5.
6.
6.
6.
6.
7.
7.
7.
7.
7.
8.
8.
8.
8.
9.
9.
9.
10.
10.
10.
10.
10.
10.
10.3.2 フランス .........................................................................................................................................................................................................
10.
10.
10.
10.
10.
10.
10.
10.
10.
10.
10.
10.
10.
10.
10.
10.5.1 ブラジル ...............................................................................................................................................................................................................
10.
10.
10.
10.
10.
10.
10.
11.
11.
11.
11.
11.
11.
11.
11.
12.1 アンジオダイナミクス株式会社
12.
12.
12.
12.
12.
12.
12.
12.
12.
12.
12.
12.
12.
12.
12.
12.
12.
12.
12.
12.
12.
12.
12.
12.
12.
12.
12.
12.
12.
12.
12.
12.
12.
12.
12.
12.
12.
12.150
12.151
12.6.5 SWOT ANALYSIS ............................................................................................................................................ 151 12.6.6 KEY STRATEGIES ............................................................................................................................................ 152
12.
12.
12.
12.
12.
12.
12.
12.
12.
12.
12.
12.
12.
12.
12.9 PAKUMEDEDICAL PRODUCTS GmbH .................................................................................................................................................................................................
12.
12.
12.
12.
12.
12.
12.
12.
12.
12.
12.
12.
12.
ページTOPに戻る
Summary Implantable Port Market Research Report by Type (Silicone, Polyurethane, Titanium), By Application (Chemotherapy, Antibiotic Therapy, Total Parenteral Nutrition, Blood Transfusion), By End User (Hospitals, Ambulatory Surgical Centers, Specialized Clinics), By Insertion Method (Surgical Insertion, Percutaneous Insertion) Forecast to 2035
Market Overview
According to MRFR analysis, the Implantable Port Market Size is expected to reach USD 3,290.28 million by 2024. The implantable port market is estimated to grow at a CAGR of 6.21% between 2025 and 2035.
One of the key reasons propelling the Implantable Port Market Industry forward is the increased prevalence of chronic diseases around the world. As cancer, diabetes, and renal illnesses become increasingly common, the demand for dependable and effective long-term pharmaceutical delivery techniques, such as implantable ports, has increased. These ports offer an efficient solution for patients who require regular infusions or blood draws, allowing healthcare personnel to administer medication with minimum discomfort and consequences. With healthcare systems increasingly focused on improving patient outcomes and the necessity for long-term drug administration, implanted port technology emerges as a potential option. Furthermore, the increased demand for outpatient therapies and chronic condition care that do not require frequent hospital visits increases the attraction and requirement of these devices. Advances in technology have also enhanced the design and functionality of implantable ports, resulting in greater acceptance among healthcare professionals and patients. The increased awareness of the advantages of employing implantable ports in terms of safety, efficacy, and comfort accelerates their adoption. All of these reasons contribute to the robust growth of the Implantable Port Market Industry.
Market Segment insights
The global implantable port market is divided into three segments based on material type: silicone, polyurethane, and titanium. Titanium had the biggest market share in 2024 and is expected to grow the fastest during the forecast period (2025-2035).
The market is divided into four segments based on application: chemotherapy, antibiotic therapy, complete parenteral nutrition, and blood transfusion.
The market is divided into three segments based on the end user: hospitals, ambulatory surgery centers, and specialist clinics.
The market has been divided into two segments based on the manner of insertion: surgical and percutaneous.
Regional insights
The global implantable port market is divided into five regions: North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. North America held the biggest market share in 2024 and is expected to reach USD 2,416.61 million by 2035. However, Asia-Pacific is expected to develop at the fastest CAGR of 8.32% over the projection period.
The North American implantable port market was worth USD 1,382.75 million in 2024, and it is expected to increase at a CAGR of 5.20% over the forecast period. North America is further divided into the United States and Canada.
The Europe implantable port market was worth USD 972.35 million in 2024 and is expected to increase at a CAGR of 6.41% over the forecast period.
The Asia-Pacific implantable port market was worth USD 667.57 million in 2024, and it is expected to increase at a CAGR of 8.32% over the forecast period. Asia-Pacific is further divided into China, India, Japan, South Korea, Malaysia, Thailand, Indonesia, and the Rest of Asia-Pacific.
Major Players
Easton Medical, Baxter International, Zyga Technology, Terumo, Apex Medical Technologies, Medtronic, Boston Scientific, Cook Medical, AngioDynamics, Kirwan Surgical Products, Smith's Medical, Nitinol Devices Corporation, C R Bard, Stryker, and Halyard Health are among the key players in the implantable port market.
ページTOPに戻る
Table of Contents TABLE OF CONTENTS
1 EXECUTIVE SUMMARY ............................................................................................................... 19
1.1 OVERVIEW .................................................................................................................................................................... 19
1.2 MARKET ATTRACTIVENESS ANALYSIS ........................................................................................................... 20
1.3 GLOBAL IMPLANTABLE PORT MARKET, BY MATERIAL TYPE ................................................................ 21
1.4 GLOBAL IMPLANTABLE PORT MARKET, BY APPLICATION ...................................................................... 22
1.5 GLOBAL IMPLANTABLE PORT MARKET, BY END USER .............................................................................. 23
1.6 GLOBAL IMPLANTABLE PORT MARKET, BY INSERTION METHOD ........................................................ 24
1.7 GLOBAL IMPLANTABLE PORT MARKET, BY REGION ................................................................................... 25
2 MARKET INTRODUCTION ............................................................................................................ 27
2.1 DEFINITION .................................................................................................................................................................. 27
2.2 SCOPE OF THE STUDY .............................................................................................................................................. 27
2.3 RESEARCH OBJECTIVE ............................................................................................................................................ 27
2.4 MARKET STRUCTURE .............................................................................................................................................. 27
3 RESEARCH METHODOLOGY ...................................................................................................... 28
3.1 OVERVIEW .................................................................................................................................................................... 28
3.2 DATA FLOW .................................................................................................................................................................. 30
3.2.1 Data Mining Process ....................................................................................................................................... 30
3.3 PURCHASED DATABASE: ......................................................................................................................................... 31
3.4 SECONDARY SOURCES: ............................................................................................................................................ 32
3.4.1 Secondary Research Data Flow: ....................................................................................................................... 33
3.5 PRIMARY RESEARCH: ............................................................................................................................................... 34
3.5.1 Primary Research Data Flow: .......................................................................................................................... 35
3.5.2 Primary Research: Number of Interviews conducted ........................................................................................ 36
3.5.3 Primary Research: Regional Coverage ............................................................................................................. 36
3.6 APPROACHES FOR MARKET SIZE ESTIMATION: ........................................................................................... 37
3.6.1 Revenue Analysis Approach ............................................................................................................................ 37
3.7 DATA FORECASTING................................................................................................................................................. 38
3.7.1 Data forecasting Type ..................................................................................................................................... 38
3.8 DATA MODELING ........................................................................................................................................................ 39
3.8.1 Microeconomic Factor Analysis: ...................................................................................................................... 39
3.8.2 Data modeling: ............................................................................................................................................... 40
3.9 TEAMS AND ANALYST CONTRIBUTION ........................................................................................................... 42
4 MARKET DYNAMICS .................................................................................................................... 44
4.1 INTRODUCTION ........................................................................................................................................................... 44
4.2 DRIVERS ......................................................................................................................................................................... 44
4.2.1 Increasing Incidences of Chronic Diseases across the globe............................................................................. 44
4.2.2 Technological Advancements .......................................................................................................................... 45
4.2.3 Better Healthcare Access ................................................................................................................................ 46
4.3 RESTRAINTS ................................................................................................................................................................ 47
4.3.1 High Cost of Implantation ............................................................................................................................... 47
4.3.2 Surgical Risks ................................................................................................................................................. 47
4.4 OPPORTUNITY ............................................................................................................................................................. 48
4.4.1 Expansion in Emerging Markets ....................................................................................................................... 48
4.4.2 Growing Aging Population ............................................................................................................................... 48
5 MARKET FACTOR ANALYSIS ...................................................................................................... 49
5.1 VALUE CHAIN ANALYSIS ....................................................................................................................................... 49
5.1.1 R&D ............................................................................................................................................................... 49
5.1.2 Manufacturing ................................................................................................................................................ 49
5.1.3 Marketing and Distribution & Channel .............................................................................................................. 49
5.1.4 Post-market Surveillance ................................................................................................................................ 50
5.2 PORTER'S FIVE FORCES MODEL ........................................................................................................................... 50
5.2.1 Threat of New Entrants ................................................................................................................................... 51
5.2.2 Bargaining Power of Suppliers ......................................................................................................................... 51
5.2.3 Threat of Substitutes ...................................................................................................................................... 52
5.2.4 Bargaining Power of Buyers ............................................................................................................................ 52
5.2.5 Intensity of Rivalry .......................................................................................................................................... 52
5.3 IMPACT OF COVID-19 ON THE GLOBAL IMPLANTABLE PORT MARKET ............................................... 53
6 GLOBAL IMPLANTABLE PORT MARKET, BY MATERIAL TYPE ................................................. 55
6.1 OVERVIEW .................................................................................................................................................................... 55
6.2 SILICONE ........................................................................................................................................................................ 57
6.3 POLYURETHANE ........................................................................................................................................................ 58
6.4 TITANIUM ..................................................................................................................................................................... 58
7 GLOBAL IMPLANTABLE PORT MARKET, BY APPLICATION ...................................................... 59
7.1 OVERVIEW .................................................................................................................................................................... 59
7.2 CHEMOTHERAPY ....................................................................................................................................................... 61
7.3 ANTIBIOTIC THERAPY ............................................................................................................................................. 62
7.4 TOTAL PARENTERAL NUTRITION ...................................................................................................................... 62
7.5 BLOOD TRANSFUSION .............................................................................................................................................. 63
8 GLOBAL IMPLANTABLE PORT MARKET, BY END USER ........................................................... 64
8.1 OVERVIEW .................................................................................................................................................................... 64
8.2 HOSPITALS ................................................................................................................................................................... 66
8.3 AMBULATORY SURGICAL CENTERS ................................................................................................................... 67
8.4 SPECIALIZED CLINICS ............................................................................................................................................... 67
9 GLOBAL IMPLANTABLE PORT MARKET, BY INSERTION METHOD ......................................... 68
9.1 OVERVIEW .................................................................................................................................................................... 68
9.2 SURGICAL INSERTION .............................................................................................................................................. 70
9.3 PERCUTANEOUS INSERTION ................................................................................................................................. 71
10 GLOBAL IMPLANTABLE PORT MARKET, BY REGION ............................................................... 72
10.1 OVERVIEW .................................................................................................................................................................... 72
10.2 NORTH AMERICA ....................................................................................................................................................... 74
10.2.1 US.................................................................................................................................................................. 77
10.2.2 CANADA ........................................................................................................................................................ 78
10.3 EUROPE .......................................................................................................................................................................... 80
10.3.1 GERMANY ...................................................................................................................................................... 83
10.3.2 FRANCE ......................................................................................................................................................... 84
10.3.3 UK ................................................................................................................................................................. 86
10.3.4 ITALY ............................................................................................................................................................. 88
10.3.5 SPAIN ............................................................................................................................................................ 90
10.3.6 RUSSIA .......................................................................................................................................................... 92
10.3.7 REST OF EUROPE ............................................................................................................................................ 94
10.4 ASIA-PACIFIC ............................................................................................................................................................... 96
10.4.1 CHINA ............................................................................................................................................................ 99
10.4.2 INDIA ............................................................................................................................................................. 100
10.4.3 JAPAN ........................................................................................................................................................... 102
10.4.4 SOUTH KOREA ................................................................................................................................................ 103
10.4.5 MALAYSIA ..................................................................................................................................................... 104
10.4.6 THAILAND ...................................................................................................................................................... 106
10.4.7 INDONESIA ..................................................................................................................................................... 107
10.4.8 REST OF ASIA-PACIFIC ................................................................................................................................... 108
10.5 SOUTH AMERICA ....................................................................................................................................................... 110
10.5.1 BRAZIL ........................................................................................................................................................... 113
10.5.2 MEXICO ......................................................................................................................................................... 114
10.5.3 ARGENTINA ................................................................................................................................................... 116
10.5.4 REST OF SOUTH AMERICA .............................................................................................................................. 117
10.6 MIDDLE EAST AND AFRICA .................................................................................................................................... 119
10.6.1 GCC COUNTRIES............................................................................................................................................. 122
10.6.2 SOUTH AFRICA ............................................................................................................................................... 123
10.6.3 REST OF MIDDLE EAST AND AFRICA ................................................................................................................ 125
11 COMPETITIVE LANDSCAPE ........................................................................................................ 128
11.1 INTRODUCTION ........................................................................................................................................................... 128
11.2 COMPANY MARKET SHARE ANALYSIS, 2024 (VALUE) ............................................................................... 128
11.3 COMPETITOR DASHBOARD..................................................................................................................................... 129
11.4 PUBLIC PLAYERS STOCK SUMMARY ................................................................................................................. 130
11.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL .............................................................................. 130
11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES ............................................................................................ 130
11.6.1 DONATION ..................................................................................................................................................... 130
11.6.2 AGREEMENT .................................................................................................................................................. 131
12 COMPANY PROFILES .................................................................................................................. 132
12.1 ANGIODYNAMICS, INC. ............................................................................................................................................. 132
12.1.1 COMPANY OVERVIEW ..................................................................................................................................... 132
12.1.2 FINANCIAL OVERVIEW .................................................................................................................................... 133
12.1.3 PRODUCTS/SOLUTIONS/SERVICES OFFERED ................................................................................................... 134
12.1.4 KEY DEVELOPMENTS ...................................................................................................................................... 135
12.1.5 SWOT ANALYSIS ............................................................................................................................................ 136
12.1.6 KEY STRATEGIES ............................................................................................................................................ 136
12.2 B. BRAUN MELSUNGEN AG .................................................................................................................................... 137
12.2.1 COMPANY OVERVIEW ..................................................................................................................................... 137
12.2.2 FINANCIAL OVERVIEW .................................................................................................................................... 138
12.2.3 PRODUCTS/SOLUTIONS/SERVICES OFFERED ................................................................................................... 138
12.2.4 KEY DEVELOPMENTS ...................................................................................................................................... 139
12.2.5 SWOT ANALYSIS ............................................................................................................................................ 139
12.2.6 KEY STRATEGIES ............................................................................................................................................ 139
12.3 BECTON, DICKINSON AND COMPANY (BD) ....................................................................................................... 140
12.3.1 COMPANY OVERVIEW ..................................................................................................................................... 140
12.3.2 FINANCIAL OVERVIEW .................................................................................................................................... 141
12.3.3 PRODUCTS/SOLUTIONS/SERVICES OFFERED ................................................................................................... 141
12.3.4 KEY DEVELOPMENTS ...................................................................................................................................... 142
12.3.5 SWOT ANALYSIS ............................................................................................................................................ 142
12.3.6 KEY STRATEGIES ............................................................................................................................................ 143
12.4 COOK MEDICAL LLC ................................................................................................................................................... 144
12.4.1 COMPANY OVERVIEW ..................................................................................................................................... 144
12.4.2 FINANCIAL OVERVIEW .................................................................................................................................... 144
12.4.3 PRODUCTS/SOLUTIONS/SERVICES OFFERED ................................................................................................... 145
12.4.4 KEY DEVELOPMENTS ...................................................................................................................................... 145
12.4.5 SWOT ANALYSIS ............................................................................................................................................ 145
12.4.6 KEY STRATEGIES ............................................................................................................................................ 146
12.5 DISTRICLASS MEDICAL SA ..................................................................................................................................... 147
12.5.1 COMPANY OVERVIEW ..................................................................................................................................... 147
12.5.2 FINANCIAL OVERVIEW .................................................................................................................................... 147
12.5.3 PRODUCTS/SOLUTIONS/SERVICES OFFERED ................................................................................................... 147
12.5.4 KEY DEVELOPMENTS ...................................................................................................................................... 147
12.5.5 SWOT ANALYSIS ............................................................................................................................................ 148
12.5.6 KEY STRATEGIES ............................................................................................................................................ 148
12.6 VYGON ............................................................................................................................................................................ 149
12.6.1 COMPANY OVERVIEW ..................................................................................................................................... 149
12.6.2 FINANCIAL OVERVIEW .................................................................................................................................... 150
12.6.3 PRODUCTS/SOLUTIONS/SERVICES OFFERED ................................................................................................... 150
12.6.4 KEY DEVELOPMENTS ...................................................................................................................................... 151
12.6.5 SWOT ANALYSIS ............................................................................................................................................ 151 12.6.6 KEY STRATEGIES ............................................................................................................................................ 152
12.7 SILMAG AG.................................................................................................................................................................... 153
12.7.1 COMPANY OVERVIEW ..................................................................................................................................... 153
12.7.2 FINANCIAL OVERVIEW .................................................................................................................................... 153
12.7.3 PRODUCTS/SOLUTIONS/SERVICES OFFERED ................................................................................................... 153
12.7.4 KEY DEVELOPMENTS ...................................................................................................................................... 153
12.7.5 SWOT ANALYSIS ............................................................................................................................................ 154
12.7.6 KEY STRATEGIES ............................................................................................................................................ 154
12.8 POLY MEDICURE LTD ................................................................................................................................................ 155
12.8.1 COMPANY OVERVIEW ..................................................................................................................................... 155
12.8.2 FINANCIAL OVERVIEW .................................................................................................................................... 156
12.8.3 PRODUCTS/SOLUTIONS/SERVICES OFFERED ................................................................................................... 156
12.8.4 KEY DEVELOPMENTS ...................................................................................................................................... 158
12.8.5 SWOT ANALYSIS ............................................................................................................................................ 158
12.8.6 KEY STRATEGIES ............................................................................................................................................ 159
12.9 PAKUMEDMEDICAL PRODUCTS GMBH ............................................................................................................. 160
12.9.1 COMPANY OVERVIEW ..................................................................................................................................... 160
12.9.2 FINANCIAL OVERVIEW .................................................................................................................................... 160
12.9.3 PRODUCTS/SOLUTIONS/SERVICES OFFERED ................................................................................................... 161
12.9.4 KEY DEVELOPMENTS ...................................................................................................................................... 161
12.9.5 SWOT ANALYSIS ............................................................................................................................................ 162
12.9.6 KEY STRATEGIES ............................................................................................................................................ 162
12.10 SOPHYSA ....................................................................................................................................................................... 163
12.10.1 COMPANY OVERVIEW ..................................................................................................................................... 163
12.10.2 FINANCIAL OVERVIEW .................................................................................................................................... 163
12.10.3 PRODUCTS/SOLUTIONS/SERVICES OFFERED ................................................................................................... 164
12.10.4 KEY DEVELOPMENTS ...................................................................................................................................... 164
12.10.5 SWOT ANALYSIS ............................................................................................................................................ 164
12.10.6 KEY STRATEGIES ............................................................................................................................................ 165
13 DATA CITATIONS ......................................................................................................................... 166
ページTOPに戻る
Market Research Future社の 医療分野 での最新刊レポート
-
抗肥満薬市場調査レポート：治療タイプ別（セロトニン・ノルエピネフリン再取り込み阻害薬、選択的セロトニン2C受容体作動薬、ノルエピネフリン・ドパミン再取り込み阻害薬）、リパーゼ阻害薬、GLP-1受容体作動薬、併用薬、その他）、薬物タイプ別（処方薬、市販薬）、作用機序別（中枢性抗肥満薬、末梢性抗肥満薬）、投与経路別（経口、皮下）、流通チャネル別（病院薬局、小売薬局、オンライン薬局）、地域別（北米、欧州、アジア太平洋、南米、中東、アフリカ） 2035年までの予測
-
ジェネリック医薬品市場調査レポート：適応症別（中枢神経系（CNS）、循環器、泌尿器、腫瘍、呼吸器、その他）、投与経路別（経口、局所、非経口、その他）、流通チャネル別（病院薬局、小売薬局、オンライン薬局）、地域別（北米、欧州、アジア太平洋地域、その他の地域） 2035年までの予測
-
多発性硬化症治療装置市場調査レポート：タイプ別[原発性進行性多発性硬化症（PPMS）、二次性進行性多発性硬化症（SPMS）、再発寛解型多発性硬化症（RRMS）、臨床的孤立症候群（CIS）]、治療装置別[電気刺激装置（機能的電気刺激（FES）、経皮的電気神経刺激（TENS）, 神経刺激装置（脊髄刺激（SCS）, 脳深部刺激（DBS））]、エンドユーザー別（病院＆クリニック, 外来手術センター）、地域別（北米, 欧州, アジア太平洋, 南米, 中東およびアフリカ）2032年までの予測
-
Peptide Cosmetic API Research Report by Application (Anti-Aging & Wrinkle Reduction, Skin Repair & Regeneration, Moisturizing & Hydration, Whitening & Brightening, Hair Care, Anti-Inflammatory & Soothing), by Source (Plant-Derived Peptides, Animal-Derived Peptides, Bioengineered Peptides, Chemically Synthesized), by End-Use Industry (Skincare, Haircare, Injectable Cosmetics, Others), by Region (North America, Europe, APAC, South America, MEA) Forecast till 2035
-
Ischemic Stroke Surgery Market Research Report by Type of Surgery (Thrombectomy, Revascularization Surgery, Carotid Endarterectomy, Angioplasty, Others), by Product Type (Catheters, Aspiration System, Guidewire, Microcatheter, Others), by End-User (Hospitals and Clinics, Ambulatory Surgical Centers, Others), and by Region (North America, Europe, Asia Pacific, Rest of the World) Forecast till 2035
-
アフリカの動物用医薬品市場レポート 動物種別（動物、コンパニオンアニマル）、製品別（医薬品、ワクチン、飼料添加物、衛生用品、診断薬）、流通チャネル別（小売薬局、Eコマース、その他）、地域別（エジプト、ナイジェリア、アルジェリア、チュニジア、リビア、ウガンダ、タンザニア、南スーダン、ケニア、エチオピア、アフリカのその他）の調査レポート情報 2032年までの予測
-
アルテスネート注射剤の世界市場調査レポート：純度別（アルテスネート0.99、アルテスネート0.98）、用途別（マラリア、重症マラリア、脳マラリア、合併症のないマラリア、その他の用途）、エンドユーザー別（病院、診療所、薬局、政府機関、非政府組織）、流通チャネル別（直販、流通業者および卸売業者、小売薬局、オンライン販売）、地域別（北米、欧州、APAC、南米、MEA）2032年までの予測
-
欧州液体クロマトグラフィー機器サービス市場2030年までの予測調査レポート
-
アーユルヴェーダ市場
-
アジア太平洋地域の血液病理学用バイオマーカー市場調査レポート情報：タイプ別（製品・サービス）、癌タイプ別（リンパ腫、白血病）、技術カテゴリー別（NGS、PCR、IHC、FISH、その他）、2032年までの地域別予測
よくあるご質問
Market Research Future社はどのような調査会社ですか?
マーケットリサーチフューチャー（Market Research Future）は世界市場を幅広く調査し、主要分野、地域、国レベルの調査レポートを出版しています。
下記分野については、分野毎に専... もっと見る
調査レポートの納品までの日数はどの程度ですか?
在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。
注文の手続きはどのようになっていますか?
1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。
お支払方法の方法はどのようになっていますか?
納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。
データリソース社はどのような会社ですか?
当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。
|
|
